These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2844553)

  • 1. Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists.
    Shippenberg TS; Herz A
    Eur J Pharmacol; 1988 Jul; 151(2):233-42. PubMed ID: 2844553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists.
    Shippenberg TS; Herz A
    Brain Res; 1987 Dec; 436(1):169-72. PubMed ID: 2961413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of mu and kappa opioid systems on motivational processes.
    Shippenberg TS; Herz A
    NIDA Res Monogr; 1986; 75():563-66. PubMed ID: 2829003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of chronic lithium treatment upon the motivational effects of opioids: alteration in the effects of mu- but not kappa-opioid receptor ligands.
    Shippenberg TS; Herz A
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1101-6. PubMed ID: 1848627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors.
    Shippenberg TS; Bals-Kubik R; Herz A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):53-9. PubMed ID: 8386244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerance and selective cross-tolerance to the motivational effects of opioids.
    Shippenberg TS; Emmett-Oglesby MW; Ayesta FJ; Herz A
    Psychopharmacology (Berl); 1988; 96(1):110-5. PubMed ID: 3147470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motivational effects of opioids in an animal model of prolonged inflammatory pain: alteration in the effects of kappa- but not of mu-receptor agonists.
    Shippenberg TS; Stein C; Huber A; Millan MJ; Herz A
    Pain; 1988 Nov; 35(2):179-186. PubMed ID: 2853321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of beta-endorphin and mu-opioid receptors in mediating the aversive effect of lithium in the rat.
    Shippenberg TS; Millan MJ; Mucha RF; Herz A
    Eur J Pharmacol; 1988 Sep; 154(2):135-44. PubMed ID: 2852596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.
    Mucha RF; Herz A
    Psychopharmacology (Berl); 1985; 86(3):274-80. PubMed ID: 2994144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Place-conditioning properties of mu, kappa, and sigma opioid agonists.
    Iwamoto ET
    Alcohol Drug Res; 1985-1986; 6(5):327-39. PubMed ID: 3011025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motivational properties of opioids: evidence that an activation of delta-receptors mediates reinforcement processes.
    Shippenberg TS; Bals-Kubik R; Herz A
    Brain Res; 1987 Dec; 436(2):234-9. PubMed ID: 2829990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphine-induced place preference in the CXBK mouse: characteristics of mu opioid receptor subtypes.
    Suzuki T; Funada M; Narita M; Misawa M; Nagase H
    Brain Res; 1993 Jan; 602(1):45-52. PubMed ID: 8383571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphine sex-dependently induced place conditioning in adult Wistar rats.
    Karami M; Zarrindast MR
    Eur J Pharmacol; 2008 Mar; 582(1-3):78-87. PubMed ID: 18191832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCH 23390 blocks drug-conditioned place-preference and place-aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade?
    Acquas E; Carboni E; Leone P; Di Chiara G
    Psychopharmacology (Berl); 1989; 99(2):151-5. PubMed ID: 2572027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kappa receptors mediate the peripheral aversive effects of opiates.
    Bechara A; van der Kooy D
    Pharmacol Biochem Behav; 1987 Oct; 28(2):227-33. PubMed ID: 2825221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-endorphin-(1-27) is a naturally occurring antagonist of the reinforcing effects of opioids.
    Bals-Kubik R; Herz A; Shippenberg TS
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Oct; 338(4):392-6. PubMed ID: 2854207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug reinforcement studied by the use of place conditioning in rat.
    Mucha RF; van der Kooy D; O'Shaughnessy M; Bucenieks P
    Brain Res; 1982 Jul; 243(1):91-105. PubMed ID: 6288174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists.
    Shippenberg TS; Bals-Kubik R; Huber A; Herz A
    Psychopharmacology (Berl); 1991; 103(2):209-14. PubMed ID: 1827526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory activity of mu- and kappa-selective opioid agonists.
    Taub DD; Eisenstein TK; Geller EB; Adler MW; Rogers TJ
    Proc Natl Acad Sci U S A; 1991 Jan; 88(2):360-4. PubMed ID: 1846441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid reward and aversion effects in the posterior ventral tegmental area are mediated through dissociable opiate receptor subtypes and separate amygdalar and accumbal dopamine receptor substrates.
    Ahmad T; Laviolette SR
    Psychopharmacology (Berl); 2017 Aug; 234(15):2325-2336. PubMed ID: 28669034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.